RedHill Biopharma Ltd. (RDHL) stock
RDHLNasdaqPharmaceutical Preparations
$0.38−0.01 (-1.60%)
Close on Nov 13, 2026Market cap $1.91MP/E –Yield –
RedHill Biopharma gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2024 it was 60.3%, against 47.0% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 60.3% | +13.3 |
| FY2023 | Dec 31, 2023 | 47.0% | +1.0 |
| FY2022 | Dec 31, 2022 | 46.1% | +3.7 |
| FY2021 | Dec 31, 2021 | 42.4% | −0.3 |
| FY2020 | Dec 31, 2020 | 42.7% | −21.4 |
| FY2019 | Dec 31, 2019 | 64.1% | −2.0 |
| FY2018 | Dec 31, 2018 | 66.1% | +19.1 |
| FY2017 | Dec 31, 2017 | 46.9% | −53.1 |
| FY2016 | Dec 31, 2016 | 100.0% | +0.0 |
| FY2015 | Dec 31, 2015 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | 51.0% | −18.2 |
| Q2 FY2021 | Jun 30, 2021 | 50.7% | +7.1 |
| Q2 FY2020 | Jun 30, 2020 | 32.1% | – |
| Q2 FY2019 | Jun 30, 2019 | 72.8% | – |
| Q2 FY2018 | Jun 30, 2018 | 69.1% | – |
| Q2 FY2017 | Jun 30, 2017 | 43.7% | – |
See a number that looks wrong?